HUTCHMED (China) (HCM) H2 2023 earnings summary

Executive summary

• FY2023 execution advanced global commercialization, expanded manufacturing capacity and progressed a broad late-stage pipeline, with 15+ potential NDAs and sNDAs targeted over the next 3 years.

• Reported revenue and net income rose substantially, driven in part by Takeda upfront and milestone income and lower R&D spending; oncology marketed-product revenue also grew.

Financial highlights

• Total consolidated revenue increased 97% reported (102% CER) to $838.0m; oncology/immunology marketed-product revenue rose 32% (39% CER) to $164.2m.

• Net income was $101.1m and attributable net income was $100.8m, versus net losses of $360.4m and $360.8m, respectively, in 2022.

• R&D revenue was $364.4m, including $280m recognized from Takeda’s $400m upfront payment, $32m from a $35m milestone and $34m in cost reimbursements.

• R&D expenses fell to $302.0m from $386.9m; selling and general administrative expenses were $133.2m, versus $136.1m in 2022.

• Oncology medicines in-market sales reached $213.6m, up 28% (35% CER); consolidated revenue was $528.6m for oncology/immunology and $309.4m for other ventures.

Outlook and guidance

• 2024 oncology/immunology consolidated revenue guidance is $300m–$400m, supported by a 30%–50% growth target for marketed-product revenue.

• More than 15 potential NDA and sNDA filings are targeted over the next 3 years, subject to clinical and regulatory outcomes.

• The medium-term ambition is to reach a self-sustaining business in 2025, with higher overseas product sales contribution expected in 2024.